^
    Back
    Association details:
    Biomarker:AKT1 E17K
    Cancer:Breast Cancer
    Drug:pifusertib (TAS-117) (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Invest New Drugs
    Title:

    Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations

    Published date:
    03/15/2021
    Excerpt:
    TAS-117 showed limited antitumor activity and manageable toxicity. Clinical efficacy was observed in patients with ovarian cancer harboring PIK3CA E545K mutations and in patients with breast cancer harboring PIK3CA H1047R and Akt1 E17K mutations.
    DOI:
    10.1007/s10637-021-01085-7
    Trial ID:
    NCT03017521
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    CT151 - Phase 2 study of TAS-117 in advanced solid tumors harboringphosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene aberrations

    Published date:
    03/10/2021
    Excerpt:
    TAS-117 showed limited anti-tumor activity and a manageable toxicity profile in patients with advanced solid tumors. Clinical efficacy was observed in patients with ovarian cancer harboring PIK3CA E545K mutations, and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.
    Trial ID:
    NCT03017521